Punchy impairment

28/05/21 -"In the ‘adjusted attributable net profit’ line, impairments are added back to show the undisturbed net profit attributable to shareholders. Due to the higher than-expected impairment (£-122m; ..."

Executive summary
Conflict of interest

Pages

Language

English

Published on

28/05/21

Download

You may also be interested by these reports :

11/04/24

Givaudan

Strong 1Q growth helped by high(er) FX pricing, especially in LatAm

05/04/24

DSM-Firmenich

After integrating the annual report, we have adopted a more cautious stance for 2024 and 2025 as the business recovery may be less pronounced than ...

04/04/24

Givaudan

Downgrade despite the expected good 1Q/FY24

25/03/24

EMS-CHEMIE

Stocks are up, but fundamentals will not easily follow

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue

Johnson Matthey